Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Sunday morning. The brokerage issued a sell rating on the stock.

A number of other research firms have also issued reports on CANF. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Trading Up 2.0 %

NYSE:CANF opened at $1.56 on Friday. The company has a market capitalization of $5.52 million, a P/E ratio of -0.87 and a beta of 1.36. The firm has a 50-day moving average price of $1.68 and a two-hundred day moving average price of $2.23. Can-Fite BioPharma has a twelve month low of $1.29 and a twelve month high of $4.69.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.